#1YYYYYYYY AYYAYYAYAY YYYYYYYY LYYLY YYLYY AYYAY Novartis Investor Relations XTTX YYYY AYYAY YYLYY LYYLY YYAYY AYYAY YYAYY AYYAY YYLYY LYYLY YYAYY 14 YY Y YAYYYY YY. YAYAY YY AYY YY AYYYY AYAY YYY GON-C 2/3 AYY Y YYY YYAYAY YYYYYYYY AYYAYYAYAY YAYYYY YAY YYY LYLY YYY YAY AYYYY Leqvio® FDA approval Investor call December 23, 2021 1 NOVARTIS | Reimagining Medicine#2Disclaimer This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "expected," "will," "planned," "pipeline," "outlook," or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for Leqvio, Entresto or pelacarsen, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward- looking statements. There can be no guarantee that Leqvio, Entresto or pelacarsen will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this presentation as of this date and does not undertake any obligation to update any forward-looking statements contained in this presentation as a result of new information, future events or otherwise. 2 LeqvioⓇ FDA Approval | December 23, 2021 | Novartis Investor Presentation U NOVARTIS | Reimagining Medicine#3Agenda Introduction Samir Shah, Global Head of Investor Relations Overview Marie-France Tschudin, President of Novartis Pharmaceuticals LeqvioⓇ clinical data and label David Soergel, MD, Head of Global Drug Development Cardio Renal Metabolism US market and launch readiness Victor Bulto, Head of Novartis Pharma US Q&A Samir Shah, Global Head of Investor Relations 3 Leqvio® FDA Approval | December 23, 2021 | Novartis Investor Presentation NOVARTIS | Reimagining Medicine#4Overview Marie-France Tschudin President of Novartis Pharmaceuticals U NOVARTIS | Reimagining Medicine#5We are building on our strength in cardiovascular to fundamentally improve and extend patients' lives 2015 Entresto sacubitril/valsartan Essential first choice for chronic heart failure ~15m patients 2021 ~2025 LEQVIO pelacarsen inclisiran Potential to tackle LDL-C in ASCVD at scale (TQJ230) Potential to lower CV risk for people with elevated Lp(a) ~60m patients High unmet need: CV disease leading cause of mortality Strong worldwide commercial and scientific presence Deep understanding of customer needs across primary and specialty care LDL-C - Low Density Lipoprotein Cholesterol ASCVD Atherosclerotic Cardiovascular Disease CV - Cardiovascular Lp(a) Lipoprotein(a) Note: Dates refer to US approval for EntrestoⓇ and LeqvioⓇ, to submission for pelacarsen. Population numbers refer to US & EU5 (Germany, France, Spain, Italy, UK). Source: Decision Resources Group. 5 Leqvio® FDA Approval | December 23, 2021 | Novartis Investor Presentation 1 NOVARTIS | Reimagining Medicine#6Despite availability of effective treatments, the burden of cardiovascular disease on health systems is on the rise CVD accounts for more deaths than any other disease¹ % of deaths US CVD costs to surpass 1 trillion p.a. by 20352 USD billion Other conditions 30% Injuries 9% Chronic respiratory diseases Diabetes 7% 2% Cardiovascular diseaseas 30% Other chronic diseases 9% Cancer 13% 555 2016 1,100 2035 30m patients with ASCVD in US5 900k lives lost to CVD annually in the US³ After years of decline, number of lives lost is rising again 14% of health expenditure due to CVD, more than any major diagnostic group6 CVD Cardiovascular Disease ASCVD Atherosclerotic Cardiovascular Disease 1. Bloom, D.E., et al. (2011). The Global Economic Burden of Noncommunicable Diseases. Geneva: World Economic Forum. 2. Includes direct and indirect costs. Source: AHA/ ASA Cardiovascular Disease: A costly burden for America. Projections through 2035. 3. Ahmad FB, Anderson RN. The leading causes of death in the US for 2020. JAMA. 2021;325(18):1829-1830. 4. Virani SS, et al. Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. Circulation. 2021;143(8): e254-e743. Accessed July 17,2021. 5. Wong ND et al. J Clin Lipidol. 2016;10(5):1109-1118. 6. Virani SS et al. Circulation. 2020;141(9):e139-e596. Note: The effect of Leqvio® on cardiovascular morbidity and mortality is currently being studied in the ongoing Phase III ORION-4 and VICTORION-2P trials. 6 Leqvio® FDA Approval | December 23, 2021 | Novartis Investor Presentation V NOVARTIS | Reimagining Medicine#7In the US, Leqvio® is positioned to meet the needs of 80% of statin-treated ASCVD patients currently not at LDL-C goal US ASCVD patient population¹ Diagnosed Statin treated At LDL-C goal² 4m Non-statin therapy² 1m 20m ך -80% 30m Leqvio® is uniquely positioned to address unmet needs in ASCVD A1 Adherence Effective and sustained 4 LDL-C reduction with two doses per year³, generally well-tolerated1 A2 Access Medical benefit coverage for majority of patients at launch A3 Affordability 0 USD expected co-pay for 2/3 patients at launch ASCVD - Atherosclerotic Cardiovascular Disease. LDL-C - Low Density Lipoprotein Cholesterol. 1. Ray KK, et al. N Engl J Med. 2020;382(16): 1507-1519. 2. Non-statin lipid lowering therapies include ezetimibe and PCSK9i mAbs. an initial dose, again at 3 months, and again every six months thereafter. 4. Across the 6-month dosing interval. 3. After 7 Leqvio® FDA Approval | December 23, 2021 | Novartis Investor Presentation V NOVARTIS | Reimagining Medicine#8LeqvioⓇ clinical data and label David Soergel, MD Head of Global Drug Development Cardiology, Renal, Metabolism U NOVARTIS | Reimagining Medicine#9LeqvioⓇ provides an innovative and differentiated approach to lowering LDL-C in ACSVD patients First and only siRNA LDL cholesterol lowering treatment4,5 Effective and sustained³ LDL-C reduction¹ ORION-10 Percentage change in LDL Twice-yearly dosing 1.2 Dosing scheme³ every 6 months 20 Inclisiran siRNA Double-stranded Guide strand Passenger strand Percentage change 0 Placebo Initial dose 3 months from baseline -20 -40 -60 Inclisiran -80 May integrate seamlessly into a patient's health care routine -100 0 90 150 270 330 Days 450510540 Triantennary GalNAc conjugate No. of patients Placebo 780 Inclisiran 781 762 745 758 757 724 715 737 731 698 666 670 721 691 705 9 months LDL-C - Low Density Lipoprotein Choletsterol ASCVD Atherosclerotic Cardiovascular Disease siRNA-small interfering Ribonucleic Acid 1. Ray KK, et al. N Engl J Med. 2020;382(16): 1507-1519. 2. After an initial dose, again at 3 months, and again every six months thereafter. As a strong complement to a maximally tolerated statin. 3. LDL-C reduction was maintained during each 6-month dosing interval. 4. Khvorova A, et al. N Engl J Med. 2017;376:4-7 5. Fitzgerald K, et al. N Engl J Med. 2017;376:41-51. 9 Leqvio® FDA Approval | December 23, 2021 | Novartis Investor Presentation NOVARTIS | Reimagining Medicine#1050 years of evidence demonstrate that effective and sustained LDL-C reduction improves cardiovascular outcomes*1,2 Log-linear association per unit change in LDL-C and the risk of cardiovascular disease5 Proportional Reduction in Risk of CHD (%) 70 50 60 siRNA e.g. LeqvioⓇ 50 mAbs 40 Statins 30 20 10 0 0 Meta-analyses of Mendelian randomization studies (N=194,427) Median follow-up 52 years 10 20 30 40 Meta-analyses of Randomized controlled trials (N=196,552) Median follow-up 5 years 50 60 70 Each mmol/L reduction in LDL-C reduces the relative risk of ASCVD events by 20% after 3 years and 1.5% in each subsequent year³ Relationship between LDL-C and MACE is supported by clinical trials involving ~500k patients³,4 Relation between LDL-C and outcomes is well established Long-term exposure to lower LDL-C (mg/dL) LDL-C - Low Density Lipoprotein Cholesterol ASCVD Atherosclerotic Cardiovascular Disease 2. CTT MACE Major Adverse Cardiovascular Events CV Cardiovascular 1. Silverman MG, et al. JAMA. 2016;316(12):1289-1297. Collaboration. Lancet 2015;385:1397-1405. 3. Cholesterol Treatment Trialists' (CTT) Collaboration, et al. Lancet. 2010;376(9753):1670-1681. 4. Wang N, et al. Lancet Diabetes Endocrinol. 2020;8:36-49. 5. Figure adapted from Brandts J, et al. Circulation. 2020;141(11):873-876; Cholesterol Treatment Trialists(CTT) Collaboration European Heart Journal (2018) 39, 2540-2545 -doi:10.1093/eurheartj/ehx450. *Note: The effect of LeqvioⓇ on cardiovascular morbidity and mortality is currently being studied in the ongoing Phase III ORION-4 and VICTORION-2P trials. 10 Leqvio® FDA Approval | December 23, 2021 | Novartis Investor Presentation NOVARTIS | Reimagining Medicine#11Guidelines recognize evidence of link between lower LDL-C and improved outcomes³ AHA/ACC (2018)1 Clinical ASCVD LDL-C reduction by ≥50% Very high CVD risk LDL-C reduction to <70 mg/dL (1.8 mmol/L) ESC/EAS (2021)² High CV risk LDL-C reduction to <70 mg/dL (1.8 mmol/L) and LDL-C reduction by ≥50% In the real world, consistent and sustained LDL-C lowering is in many cases not achieved due to adherence, access, and affordability challenges Very high CV risk LDL-C reduction to <55 mg/dL (1.4 mmol/L) and LDL-C reduction by ≥50% ASCVD Atherosclerotic 3. The effect of LDL-C - Low Density Lipoprotein Cholesterol. AHA American Heart Association. ACC American College of Cardiology. ESC European Society of Cardiology. EAS - European Atherosclerosis Society. Cardiovascular Disease. CVD Cardiovascular Disease. CV-Cardiovascular. 1. Grundy SM, et al. J Am Coll Cardiol. 2019;73(24):3237-3241. 2. Visseren FLJ et al. Eur Heart J. 2021; Sep 7; 42(34):3227-3337. LeqvioⓇ on cardiovascular morbidity and mortality is currently being studied in the ongoing Phase III ORION-4 trial. 11 Leqvio® FDA Approval | December 23, 2021 | Novartis Investor Presentation NOVARTIS | Reimagining Medicine#12LeqvioⓇ delivers effective and sustained³ LDL-C reduction of up to 52%1,2 with twice-yearly HCP-administered dosing LeqvioⓇ effected significant reductions in LDL-C vs. placebo at Day 510, on top of SoC % Change in LDL-C from baseline LeqvioⓇ ORION-105 ORION-115,6 ORION-95 -51 -466 -40 Placebo 1 46 8 Difference between groups (in mean percentage change) -52% (p<0.0001) -51%6 (p < 0.0001) -48% (p<0.0001) LDL-C - Low Density Lipoprotein Cholesterol. ASCVD - Atherosclerotic Cardiovascular Disease. HCP Healthcare Professional SoC - standard of care 1. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol Kausik K. Ray, M.D., M.Phil., R. Scott Wright, M.D., David Kallend, M.D., Wolfgang Koenig, M.D., Lawrence A. Leiter, M.D., Frederick J. Raal, Ph.D., Jenna A. Bisch, B.A., Tara Richardson, B.A., Mark Jaros, Ph.D., Peter L.J. Wijngaard, Ph.D., and John J.P. Kastelein, M.D., Ph.D., for the ORION-10 and ORION-11 Investigators*; March 18, 2020, at NEJM.org.DOI: 10.1056/NEJMoa1912387. 2. Inclisiran for the Treatment of Heterozygous Familial HypercholesterolemiaFrederick J. Raal, M.D., Ph.D., David Kallend, M.B., B.S., Kausik K. Ray, M.D., M.Phil., Traci Turner, M.D., Wolfgang Koenig, M.D., R. Scott Wright, M.D., Peter L.J. Wijngaard, Ph.D., Danielle Curcio, M.B.A., Mark J. Jaros, Ph.D., Lawrence A. Leiter, M.D., and John J.P. Kastelein, M.D., Ph.D., for the ORION-9 Investigators*; March 18, 2020, at NEJM.org.DOI: 10.1056/NEJMoa1913805. 3. Across the 6-month dosing interval. 4. After an initial dose, again at 3 months, and again every six months thereafter. As a strong complement to a maximally tolerated statin 5. LeqvioⓇ prescribing information East Hanover, NJ. Novartis: 2021 6. ASCVD subjects only; ASCVD-Risk Equivalents excluded from analysis 12 LeqvioⓇ FDA Approval | December 23, 2021 | Novartis Investor Presentation V NOVARTIS | Reimagining Medicine#13Leqvio® has a well tolerated safety profile No significant safety or tolerability concerns identified with the long-term* administration of LeqvioⓇ1,2 ORION-9 (n=481)1 LeqvioⓇ ORION-10 (n=1,559)² ORION-11 (n=1,615)² Placebo LeqvioⓇ Placebo LeqvioⓇ Placebo n=241 n=240 n=781 n=778 n=811 n=804 Safety population n % n % n % n % n % n % Patients with at least 18 7.5% 33 13.8% 175 22.4% 205 26.3% 181 22.3% 181 22.5% one serious TEAE Pre-specified exploratory CV 10 4.1% 10 4.2% 58 7.4% 79 10.2% 63 7.8% 83 10.3% endpoint (MedDRA basket) ■ Most common adverse events with similar frequency in LeqvioⓇ and placebo groups ■ Adverse events associated with LeqvioⓇ were all mild or moderate in severity, transient and resolved without sequelae ■ Common adverse reactions (≥ 3%) include injection site reaction, arthralgia, urinary tract infection, diarrhea, bronchitis, pain in extremity, and dyspnea CV Cardiovascular TEAE - Treatment Emergent Adverse Event *Over 18 months. 1. Inclisiran for the Treatment of Heterozygous Familial HypercholesterolemiaFrederick J. Raal, M.D., Ph.D., David Kallend, M.B., B.S., Kausik K. Ray, M.D., M.Phil., Traci Turner, M.D., Wolfgang Koenig, M.D., R. Scott Wright, M.D., Peter L.J. Wijngaard, Ph.D., Danielle Curcio, M.B.A., Mark J. Jaros, Ph.D., Lawrence A. Leiter, M.D., and John J.P. Kastelein, M.D., Ph.D., for the ORION-9 Investigators*; March 18, 2020, at NEJM.org.DOI: 10.1056/NEJMoa1913805. 2. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL CholesterolKausik K. Ray, M.D., M.Phil., R. Scott Wright, M.D., David Kallend, M.D., Wolfgang Koenig, M.D., Lawrence A. Leiter, M.D., Frederick J. Raal, Ph.D., Jenna A. Bisch, B.A., Tara Richardson, B.A., Mark Jaros, Ph.D., Peter L.J. Wijngaard, Ph.D., and John J.P. Kastelein, M.D., Ph.D., for the ORION-10 and ORION-11 Investigators*; March 18, 2020, at NEJM.org.DOI: 10.1056/NEJMoa1912387. 13 Leqvio® FDA Approval | December 23, 2021 | Novartis Investor Presentation V NOVARTIS | Reimagining Medicine#14Large integrated program to establish Leqvio® as part of the standard of care in ASCVD management Lipid lowering Registration trials ORION-3 (Ph2 extension) ORION-5 (Ph3 HoFH) ORION-8 (Ph3 extension) Geographic expansion ORION-14 (China) Outcomes Secondary Prevention ORION-4 (Oxford) VICTORION-2-PREVENT Primary Prevention ORION-17 (Oxford) Healthcare system partnerships NHS collaboration VICTORION-SPIRIT (UK) Implementation science and RWE Initiation of treatment VICTORION-INITIATE (US) Post-ACS VICTORION-INCEPTION (US) ORION-18 (China) ORION-15 (Japan) Diverse patient populations ORION-13 (V-YOUTH) ORION-16 (V-YOUTH) >75,000 patients in >50 countries; Program expansion underway ASCVD - Atherosclerotic Cardiovascular Disease. RWE Real World Evidence 14 LeqvioⓇ FDA Approval | December 23, 2021 | Novartis Investor Presentation U NOVARTIS | Reimagining Medicine#15Leqvio® is now approved in the US with a label that contains no contraindications, warnings/precautions, or drug interactions Indication statement¹ LeqvioⓇ is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD), who require additional lowering of low-density lipoprotein cholesterol (LDL-C). Limitations of use: The effect of LeqvioⓇ on cardiovascular morbidity and mortality has not been determined. 16m addressable ASCVD patients not at LDL-C goal Dosage and administration¹ The recommended dosage of LeqvioⓇ, in combination with maximally tolerated statin therapy, is 284 mg administered as a single subcutaneous injection initially, again at 3 months, and then every 6 months; LeqvioⓇ should be administered by a healthcare professional. May seamlessly integrate into a patient's health care routine Medical benefit coverage expected HeFH-Heterozygous Familial Hypercholesterolemia ASCVD Atherosclerotic Cardiovascular Disease. LDL-C - Low Density Lipoprotein Choletsterol 1. LeqvioⓇ prescribing information East Hanover, NJ. Novartis: 2021 15 Leqvio® FDA Approval | December 23, 2021 | Novartis Investor Presentation V NOVARTIS | Reimagining Medicine#16US market and launch readiness Victor Bulto Head of Novartis Pharma US V NOVARTIS | Reimagining Medicine#17Despite the availability of lipid-lowering therapy, significant unmet need remains in ASCVD Clinical unmet need 80% of statin-treated ASCVD patients currently not at LDL-C goal¹ Non-clinical unmet need A1 Adherence Real-world challenges to adherence compromise outcomes² A2 Access A3 Affordability Considerable access hurdles for current treatments Patient out-of-pocket costs can be a barrier to access ASCVD Atherosclerotic Cardiovascular Disease LDL-C - Low Density Lipoprotein Choletsterol 1. Wong ND. Journal of Clinical Lipidology. 2016;10(5):1109-1118 2. The effect of LeqvioⓇ on cardiovascular morbidity and mortality is currently being studied in the ongoing Phase III ORION-4 and VICTORION-2P trials. 17 Leqvio® FDA Approval | December 23, 2021 | Novartis Investor Presentation V NOVARTIS | Reimagining Medicine#18A1 Adherence - real-world challenges compromise outcomes4 Statin adherence in secondary prevention¹ Not adherent² Adherent 43% 57% Non-adherent PCSK9i patient share³ 54% 12 months 76% 24 months Sustained lipid lowering reduces CV risk¹ MACE according to adherence categories in secondary prevention Cumulative incidence, % 45- 40 35 30 25 20 15- 10- 5. Log-Rank P value=.0002 0 6 12 18 24 30 36 42 Time in months Number 4015 3541 2421 1510 871 438 99 0 at risk PDC <40% PDC 40%-79% PDC ≥80% CV Cardiovascular MACE -Major Adverse Cardiovascular Event 2. Not adherent or not fully adherent within 6 months. 3. Data on file. PCSK9i - Proprotein convertase subtilisin/kexin type 9 inhibitor. PDC Percent Days Covered 1. Bansilal S, et al. J Am Coll Cardiol. 2016;68:789-801. 4. The effect of Leqvio® on cardiovascular morbidity and mortality is currently being studied in the ongoing Phase III ORION-4 and VICTORION-2P trials. 18 Leqvio® FDA Approval | December 23, 2021 | Novartis Investor Presentation V NOVARTIS | Reimagining Medicine#19A1 Adherence - Leqvio® has the potential to address adherence challenges Effective and sustained³ LDL-C reduction¹ ORION-10 Percentage change in LDL cholesterol Twice-yearly dosing 1.2 HCP administered Dosing scheme³ 20 Percentage change from baseline Placebo 0 every 6 months -20 -40 -60 Initial dose 3 months Inclisiran 9 months -80 -100 0 90 150 270 330 450510540 Days No. of patients Placebo 780 Inclisiran 781 762 745 758 757 724 715 737 731 698 666 670 721 691 705 May integrate seamlessly into a patient's health care routine No patient education on administration required LDL-C - Low Density Lipoprotein Choletsterol HCP Healthcare Professional 1. Ray KK, et al. N Engl J Med. 2020;382(16):1507-1519. 2. After an initial dose, again at 3 months, and again every six months thereafter. As a strong complement to a maximally tolerated statin. 3. LDL-C reduction was maintained during each 6-month dosing interval. 19 Leqvio® FDA Approval | December 23, 2021 | Novartis Investor Presentation 1 NOVARTIS | Reimagining Medicine#20A2 Access - majority of Leqvio® patients will be covered by medical benefit, reducing access hurdles Payer Mix Administration Acquisition Access restrictions (step edits, prior authorizations) Reimbursement of administrative effort Part B FFS (39%) Leqvio® Medicare Advantage (19%) Commercial (34%) PCSK9i mAbs HCP-administered Self-administered Buy-and-bill Buy-and-bill, specialty pharmacy Buy-and-bill, specialty pharmacy Specialty or retail pharmacy Efforts reimbursed (medical benefit) CV outcomes evidence as driver of access decisions Access mirrors FDA label Focus on efficacy, safety, cost Efforts not reimbursed More favorable Less favorable CV Cardiovascular FFS-Fee For Service HCP Healthcare Professional PCSK9i - Proprotein convertase subtilisin/kexin type 9 inhibitor mAbs monoclonal Antibodies FDA Food and Drug Administration 20 LeqvioⓇ FDA Approval | December 23, 2021 | Novartis Investor Presentation U NOVARTIS | Reimagining Medicine#21A3 Affordability - medical benefit coverage for LeqvioⓇ creates opportunity for 0 USD co-pay for 2/3 patients at launch PCSK9i abandonment rate by OOP cost¹ 41% Anticipated payer mix and co-pay for LeqvioⓇ at launch 66% Medicare Part B Commercial Anticipated co-pay 80% pay as % of eligible population 39% little as 0 USD Eligible patients pay 34% 22% Medicare 9% Advantage Other 8% 0 40-50 75-125 250-500 (Medicaid, federal) Co-pay (USD) 19% as little as 0 USD Varies; 0-20% co-insurance <10 USD $0 co-pay for 2/3 patients at launch PCSK9i - Proprotein convertase subtilisin/kexin type 9 inhibitor OOP - Out Of Pocket 1. LAAD; IQVIA US Market Access Strategy Consulting. 21 Leqvio® FDA Approval | December 23, 2021 | Novartis Investor Presentation U NOVARTIS | Reimagining Medicine#22The price of Leqvio® reflects its value as an innovative, LDL-lowering treatment that uniquely addresses key unmet needs in ASCVD Clinical benefits of Leqvio® ✓ Efficacy ✓ Safety Non-clinical benefits of LeqvioⓇ Adherence Access Leqvio provides effective and sustained LDL-C reduction up to 52% vs. placebo 1,2 LeqvioⓇ offers a demonstrated safety profile, generally well tolerated across different patient populations Effective and sustained LDL-C reduction with two HCP- administered doses per year³ Medical benefit coverage for majority of patients at launch Affordability 2/3 of patients pay as little as $0 co-pay at launch $3,250 x2 Price per dose (WAC) Doses per year³ $6,500 Annualized price ☐ ■ Value-based Cost-effective LDL-C - Low Density Lipoprotein Choletsterol ASCVD - Atherosclerotic Cardiovascular Disease HCP Healthcare Professional WAC Wholesale Acquisition Cost 1. Khvorova A, et al. N Engl J Med. 2017;376:4-7 2. Fitzgerald K, et al. N Engl J Med. 2017;376:41-51. 3. After an initial dose, again at 3 months, and again every six months thereafter. As a strong complement to a maximally tolerated statin 22 LeqvioⓇ FDA Approval | December 23, 2021 | Novartis Investor Presentation U NOVARTIS | Reimagining Medicine#23Leqvio® go-to-market model: systems engagement, complemented by broad HCP education with CRM sales team Systems of care Targets customers ■ ~200 prioritized systems Engagement approach LeqvioⓇ pathway ■ 45% currently prioritize ASCVD² ■ Cross-functional teams engaged with key systems stakeholders ■ Aim to ensure protocols in place to identify and manage ASCVD patients not at goal May leverage existing buy-and-bill infrastructure or refer to an alternative injection center ☐ HCPs Representing ~60% of NBRx volume1 Leveraging strong commercial CRM footprint Highlighting unmet need and raise importance of LDL-C May administer in-office or refer to alternative injection center ASCVD - Atherosclerotic Cardiovascular Disease HCP - Healthcare Professional CV Cardiovascular CRM Cardiovascular, Renal, Metabolic LDL-C - Low Density Lipoprotein Choletsterol 1. Data on file. 2. Data on file 23 Leqvio FDA Approval | December 23, 2021 | Novartis Investor Presentation NOVARTIS | Reimagining Medicine#24Flexibility, support and optionality will ensure seamless customer experience and timely access to Leqvio® Flexibility of acquisition and administration Robust network of >1,100 AICS ✓ ~75% of target HCPs have an AIC within 25 miles ✓ AIC locator tool available to providers and patients Support with initial acquisition and reimbursement complexity Largest access and reimbursement field team in the industry ✓ Establishing buy-and-bill infrastructure ✓ Understanding coding and reimbursement ✓ Navigating PA and medical exception process Optionality to address heterogenous customer needs Dedicated case managers ✓ Benefit verification and coverage support ✓ Co-pay assistance ✓ Billing and coding support Dedicated social workers ✓ Patient care program ✓ Adherence support LeqvioⓇ access and reimbursement website1 AIC Alternative injection center HCP Healthcare Professional PA Prior Authorization 1. Leqvio-access.com 24 Leqvio® FDA Approval | December 23, 2021 | Novartis Investor Presentation U NOVARTIS | Reimagining Medicine#25Expect modest initial ramp as we lay the foundation for multi-blockbuster potential H1 2022-laying foundation ■ High interest from early adopters ■ Independent HCPs ready for buy-and-bill ■ AICs responding to demand " " Temporary J-code Coverage to label for FFS Medicare H2 2022 - getting to scale ■ Permanent J-code available ■ ☐ Buy-and-bill capabilities established System P&T committee review complete ■ Finalization of commercial & Medicare Advantage payer coverage policies Lead indicators # of health systems/ facilities adopting LeqvioⓇ # of systems with repeat orders # of AIC facilities administering LeqvioⓇ Intent to prescribe HCP Healthcare Professional AIC - Alternative Injection Center P&T Pharmacy and Therapeutics FFS-Fee For Service 25 Leqvio® FDA Approval | December 23, 2021 | Novartis Investor Presentation NOVARTIS | Reimagining Medicine#26Confident in successful US launch Effective and sustained LDL-C reduction with twice a year maintenance dose administered by HCP ✓ Broad label covering 16m US ASCVD patients not at LDL-C goal ✓ Go-to-market model designed to overcome clinical barriers and address access, adherence and affordability Sales, reimbursement and medical teams with deep experience in the US cardiovascular market Robust network of AICs to provide acquisition and administration flexibility Value-based price per dose (USD 3,250) ✓ Comprehensive patient and HCP support programs available at launch to ensure timely access ✓ Product available from specialty distributors in early January LDL-C - Low Density Lipoprotein Cholesterol ASCVD Atherosclerotic Cardiovascular Disease AIC Alternative Injection Center HCP Healthcare Professional 1. Across the 6-month dosing interval. 26 Leqvio® FDA Approval | December 23, 2021 | Novartis Investor Presentation U NOVARTIS | Reimagining Medicine#27Q&A Samir Shah Global Head of Investor Relations NOVARTIS | Reimagining Medicine#28YYYYYYYY AYYAYYAYAY YYAYYAYYYY LY YY. YY AYYAYYAYAY YYYYYYYY AYYAYYAYAY YYYYYYYY YYAYAY YAY AYY YY. YY YYYY AYAY YYYY YAYAY YAYYYY YY AYYAYYAYAY YYAYYAYYYY AYYAYYAYAY YYYYYYYY Y YY AYY YYAYAY YAY YYY AYAY YYYY YAY TYY Y YYY YYAYAY YYYYYYYY AYYAYYAYAY YAYYYY YAY YYY LYLY YYY YAY AYYYY Thank you U NOVARTIS | Reimagining Medicine